Clinical trials: Gene Expression Profiling
Metastatic Melanoma, CNS Metastases
Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls
This study has two ultimate goals: 1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any…
- Trial name
- NCT01312506
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Myelodysplastic Syndrome
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Several previous studies (clinical and non-clinical) hypothesize that treatment with deferasirox causes a hematological improvement in transfused patients with low and intermediate-1 risk myelodysplastic syndrome.
- Trial name
- EXPHAR (NCT02663752)
- Testing
- Bone marrow aspirate, Deferasirox
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Pulmonary Hypertension
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
- Trial name
- NCT01730092
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
This study will construct tissue microarrays (TMAs) pertaining to childhood cancer. TMA technology is a recently developed one that allows for evaluating hundreds of tissue samples simultaneously on the DNA, RNA, and protein…
- Trial name
- NCT00340522
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Background: Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous…
- Trial name
- NCT01030900
- Testing
- Campath, Rituximab, EPOCH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Large B-Cell, Diffuse
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- ROBUST (NCT02285062)
- Testing
- lenalidomide, Rituximab, Cyclophosphamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 570 people
- Sponsor
- Celgene
Corona Virus Infection
Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
The aim of this effort is to study host-pathogen interaction in Egyptian patients infected with COVID-19. The investigators will perform genome-wide miRNA and transcriptome screens in the infected patients along with healthy ones…
- Trial name
- NCT04583566
- Testing
- COVID-19 Diagnostic and Assessment Tests
- Where
- 2 sites in Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tanta University
Breast Neoplasms, Postmenopausal Disorder
Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation
The purpose of this study is to evaluate whether calcitriol supplementation may reduce tumor cell proliferation and influence gene expression profile of breast cancer samples from post-menopausal patients.
- Trial name
- NCT00926315
- Testing
- calcitriol
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Metastatic Breast Cancer
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.
- Trial name
- Side-Out (NCT01074814)
- Testing
- Approved therapy will be assigned based on molecular profile and RPMA results
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Translational Drug Development
Adenomyosis
Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis
Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of the uterus. It affects about 15-20% of the female population.
- Trial name
- NAPPED II (NCT02197923)
- Testing
- Myometrial biopsy, endometrial biopsy
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Adenocarcinoma, Rectal Diseases
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. Rectal cancer treatment has improved greatly over recent years.
- Conditions
- Adenocarcinoma, Rectal Diseases, Colorectal Neoplasms, Adenocarcinoma, Mucinous
- Trial name
- MARVEL (NCT01995942)
- Where
- 19 sites in United Kingdom
- Volunteers
- 246 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Chronic Hepatitis C, Obesity
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in…
- Trial name
- NCT00322179
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Palo Alto Veterans Institute for Research
Heart Transplant Rejection
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
The goal of this observational study is to develop and validate a molecular heart rejection diagnostic system based on targeted transcriptome as a novel monitoring companion tool for heart allograft precision diagnostics…
- Trial name
- Nano-Heart (NCT06436027)
- Testing
- Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 496 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Leukemia
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of…
- Trial name
- NCT01108497
- Testing
- Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- Stanford University
Resectable Pancreatic Adenocarcinoma
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
The study aims at evaluating spatially resolved gene expression profiles of pancreatic and ampullary adenocarcinoma at favorable prognosis after surgical resection, in order to identify molecular features associated to a less…
- Trial name
- NCT05754788
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Allergic Rhinitis
Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease
Using a human pangenomic microarray, the researchers established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct groups: 1.
- Trial name
- NCT00569361
- Testing
- Collection of nasal epithelial cells
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Premature Luteinization
Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization
Previous studies have suggested that premature luteinization (PL)during controlled ovarian stimulation (COS) decreases the implantation rate due to a negative effect on the endometrium receptivity.
- Trial name
- NCT00447850
- Testing
- endometrial biopsy
- Where
- Spain
- Volunteers
- healthy volunteers welcome
- Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
Breast Cancer
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MINDACT (NCT00433589)
- Testing
- anthracycline-based, docetaxel and capecitabine, tamoxifen
- Where
- Netherlands
- Volunteers
- 6,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Genetic Predisposition to Disease, Inflammation
Gene Expression in Chronic Venous Leg Ulcers
Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries that may negatively impact the quality of life (QoL) of affected patients.
- Conditions
- Genetic Predisposition to Disease, Inflammation, Venous Leg Ulcer
- Trial name
- GECVELUS (NCT05134597)
- Testing
- Genetic assessment
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Catanzaro
Cancer, Gastrointestinal Cancer
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
- Trial name
- NCT06489041
- Testing
- Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Wake Forest University Health Sciences